To strengthen presence in Africa, Grifols announced that it will establish an intravenous (IV) solutions production plant in Nigeria for Dozie and Dozie’s Pharma Nig Ltd. The new the manufacturing facility at initial phase will produce as many as 5.5 million intravenous solutions.
- Dozie and Dozie’s Pharma Nig Ltd., a leading provider of healthcare products in the country and surrounding region.
- The intravenous solutions used in hospitals and other healthcare institutions in Nigeria and other African countries.
The prominent deals and expansions by Grifols are mentioned below:
Sep 2020: Grifols announced that it had entered into an agreement to acquire the remaining equity of Alkahest, Inc. for approximately $146 million. The Silicon Valley-based biotechnology company Alkahest develops therapies derived from blood to treat neurological diseases.
July 2020: Grifols had acquired 10% of Bloodbuy (BloodSolutions), a cloud-based marketplace that facilitates buying and selling of blood components in the U.S.
July 2020: Grifols, announced that it had executed purchase arrangements with the South Korean-based GC Pharma (Group) whereby Grifols will acquire the Montreal-based plasma fractionation facility and two purification facilities, along with 11 U.S.-based plasma collection centers for a total amount of US$460 million.
June 2020: Hologic, Inc, a global medical technology company with a speciality in molecular diagnostics for infectious diseases, and Grifols, announced that they would combine forces in Spain to substantially increase the countrys testing capacity for COVID-19 to help meet its high testing needs to help fight the COVID-19 pandemic. This is especially relevant as the country is gradually de-escalating and tourism will soon return which will significantly help re-open the economy safely.
May 2020: Grifols had formalized the acquisition of 517,000 square feet in the municipality of Lliçà de Vall (Vallès Oriental Region) to grow its industrial capacity in Barcelona. The agreement was finally closed was supposed to occur in 2018, leading to a two-year delay in the start of the project.
Grifols, headquartered in Barcelona, Spain, a leading global producer of plasma-derived medicines. The company is also a global leader in the development of innovative diagnostic solutions. The company has four divisions Bioscience, Diagnostic, Hospital and Bio Supplies to develop, produce and market innovative solutions and services in approximately 100 countries. The company has more than 24,000 employees in 30 countries across the world.